Agenda

Date and TimeTitle
Jun 23, 2022
12:30pm - 1:10pm (Pacific)
Classical Hodgkin Lymphoma (cHL) and Peripheral T-Cell Lymphoma (PTCL) Lymphoma Clinical Update

Goals of the LCU Presentation:

Classical Hodgkin Lymphoma

  • Review the epidemiology and etiology of Hodgkin lymphoma
  • Discuss the clinical workup and diagnosis of classical Hodgkin lymphoma (cHL)
  • Review how cHL has historically been treated
  • Discuss the evolving treatment paradigm for cHL from risk-adapted to response-adapted approach
  • Review the current NCCN guidelines

Peripheral T-cell Lymphoma (PTCL)

  • Review the epidemiology of PTCL
  • Review the subtypes of PTCL with a focus on nodal subtypes
  • Review how PTCL has historically been treated
  • Discuss the unmet need in treating PTCI
  • Review the current NCCN guidelines

 

Sponsored by Seagen, Inc. 

This is a Non-CME presentation. 

Jun 23, 2022
1:55pm - 2:45pm (Pacific)
Keynote Address: Welcome & Introductions

1:55PM PT | Welcome and Introductions
Won Seog Kim, MD, PhD

2:00PM PT |  Introduction of Keynote Speaker
Pier Luigi Zinzani, MD

2:06PM PT | Keynote Address: The Gradual Evolution of Treatment in PTCL: Is it Time to Embrace a New Punctuated Equilibrium?
Owen A. O'Connor, MD, PhD

Jun 23, 2022
2:45pm - 3:05pm (Pacific)
Visit Sponsors, Poster Hall & Networking Forum

Visit our Sponsors Wall HERE

Visit our Poster Hall HERE 

Visit our Networking Forum HERE

Jun 23, 2022
3:05pm - 4:45pm (Pacific)
Session I: Epidemiology & Classification

3:05PM PT | Introduction & In Memoriam: D. Thomas Waldmann and Dr. Joe Bertino
Francine M. Foss, MD
Owen A. O’Connor, MD, PhD

3:10PM PT | A Focus on Rare PTCL Subtypes: Clinicopathologic Correlations
Pier Paolo Piccaluga, MD, PhD

3:25PM PT | Recommendations from the Clinical Advisory Committee of the International Consensus Classification of Myeloid and Lymphoid Neoplasms
Elaine S. Jaffe, MD

3:40PM PT | 2022 International Consensus Classification (ICC) Guidelines for Follicular Helper and Intestinal T-Cell Lymphomas
Laurence de Leval, MD, PhD

3:55PM PT | Agent Orange and the Link with CTCL and PTCL in Veterans: What Does the Data Say?
Helen Ma, MD

4:10PM PT | Methyltransferase Inhibitors Restore SATB1 Protective Activity Against Cutaneous T cell Lymphoma in Mice
Carly Harro

4:25PM PT | Panel Discussion
Francine M. Foss, MD
Pier Paolo Piccaluga, MD, PhD
Elaine S. Jaffe, MD
Laurence de Leval, MD, PhD
Helen Ma, MD
Carly Harro

Jun 24, 2022
8:10am - 9:47am (Pacific)
Session II: Molecular Biology & Pathogenesis

8:10AM PT | Welcome
Won Seog Kim, MD, PhD

8:15AM PT | Molecular Classification of the PTCL: What's New and How Will it Influence Practice?
Javeed Iqbal, PhD

8:45AM PT | Most Recent Advances in the Pathogenesis of T-Cell Lymphoma
Kojo S. J. Elenitoba-Johnson, MD

9:00AM PT | How Does One Measure MRD in Patients with Hematologic Malignancies, and Why?
Matthew Ahearne, MD, MRCP

9:15AM PT | The Status of MRD Analyses in TCLF
John Chan, MD

Programmed Cell Death Protein 1 Signaling and Lipid Metabolism in Peripheral T-Cell Lymphoma
Tim Wartewig, PhD (Available for On-Demand Only)

9:30AM PT | Panel Discussion
Won Seog Kim, MD, PhD
Javeed Iqbal, PhD
Tim Wartewig, PhD
Kojo S. J. Elenitoba-Johnson, MD
Matthew Ahearne, MD, MRCP
John Chan, MD

Jun 24, 2022
9:48am - 10:00am (Pacific)
Visit Sponsors, Poster Hall & Networking Forum

Visit our Sponsors Wall HERE

Visit our Poster Hall HERE 

Visit our Networking Forum HERE

Jun 24, 2022
10:00am - 11:40am (Pacific)
Session III: T-Cell Lymphoma Subtypes

10:00AM PT | Welcome
Won Seog Kim, MD, PhD

10:05AM PT | Liquid Biopsy in PTCLs: Potential Clinical Applications and Limitation
Won Seog Kim, MD, PhD

10:20AM PT | Genetic Susceptibility to NKTCL?
Jin-Xin Bei, PhD

10:35AM PT | Prognostic Value of Single-Nucleotide Polymorphisms for Extranodal Natural Killer/T-Cell Lymphoma: The Identification of Risk Factors in the Molecular Era
Quingquing Cai, MD, PhD

10:50AM PT | How Animal Models of Adult T-Cell Leukemia Have Changed Our Thinking Around Disease Biology
Ali Bazarbachi, MD, PhD

11:05AM PT | The role of Tet2 in Select subtypes of PTCL: A focus on AITL and PTCL-TFH.
Teresa M. Palomero, PhD

11:20AM PT | Genomic Landscape of ATLL
Keisuke Kataoka, MD, PhD

11:35AM PT | Panel Discussion
Won Seog Kim, MD, PhD
Jin-Xin Bei, PhD
Quingquing Cai, MD, PhD
Ali Bazarbachi, MD, PhD
Teresa M. Palomero, PhD
Keisuke Kataoka, MD, PhD

Jun 24, 2022
11:46am - 12:30pm (Pacific)
Visit Sponsors, Poster Hall & Networking Forum

Visit our Sponsors Wall HERE

Visit our Poster Hall HERE 

Visit our Networking Forum HERE

Jun 24, 2022
12:30pm - 1:00pm (Pacific)
Case Study Presentations: Patient profiles based on experiences with POTELIGEO

Sponsored by Kyowa Kirin

This is a Non-CME presentation. 

Jun 24, 2022
1:30pm - 1:35pm (Pacific)
Visit Sponsors, Poster Hall & Networking Forum

Visit our Sponsors Wall HERE

Visit our Poster Hall HERE 

Visit our Networking Forum HERE

Jun 24, 2022
1:35pm - 3:40pm (Pacific)
Session IV: Treatment – Chemotherapy vs Non-Chemotherapy Options in the Front-Line

1:35PM PT | Introduction
Owen A. O'Connor, MD, PhD

1:40PM PT | CHOP-Romidepsin in the Front Line
Michael Crump, MD

1:55PM PT | Still CHOP? The Merits or NOT of CHOP Addition Studies
Seok Jin Kim, MD, PhD

2:10PM PT | What’s the Argument for Non-Chemotherapy Options in the Front Line
Enrica Marchi, MD, PhD

2:25PM PT | Live Debate: I Transplant All Eligible Patients in the Front-Line 
Norbert Schmitz, MD, PhD

2:40PM PT | I Never Recommend ASCT in the Front Line
Pier Luigi Zinzani, MD

2:55PM PT | The Nowadays Role of AlloSCT in the Treatment of PTCL
Paolo Corradini, MD

3:10PM PT | Panel Discussion 
Owen A. O'Connor, MD, PhD
Seok Jin Kim, MD, PhD
Enrica Marchi, MD, PhD
Norbert Schmitz, MD, PhD

Jun 24, 2022
3:40pm - 3:50pm (Pacific)
Visit Sponsors, Poster Hall & Networking Forum

Visit our Sponsors Wall HERE

Visit our Poster Hall HERE 

Visit our Networking Forum HERE

Jun 24, 2022
3:50pm - 5:20pm (Pacific)
Session V: CTCL

3:50PM PT | Introduction
Owen A. O'Connor, MD, PhD

3:55PM PT | Quantitating Clinical Benefits of New Treatments in CTCL: Is it Time to Move on from SWAT?
H. Miles Prince, MD

4:10PM PT | What Have we Learned about the Treatment of Advanced Stage MF from the ProClipi Registry?
Julia Scarisbrick, MD, MBChB

4:25PM PT | Transformed MF: Clinical Approaches and Novel Molecular Insights
Francine M. Foss, MD
Pei-Ling Chen, MD, PhD

4:40PM PT | Novel Agents and Combinations in CTCL
Michael Girardi, MD 

4:55PM PT | Panel Discussion 
Owen A. O'Connor, MD, PhD
H. Miles Prince, MD
Julia Scarisbrick, MD, MBChB
Francine M. Foss, MD
Michael Girardi, MD 

 

Jun 24, 2022
5:20pm - 5:25pm (Pacific)
Visit Sponsors, Poster Hall, & Networking Forum

Visit our Sponsors Wall HERE

Visit our Poster Hall HERE 

Visit our Networking Forum HERE

Jun 24, 2022
5:25pm - 6:15pm (Pacific)
Poster Presentations
Jun 25, 2022
8:05am - 10:10am (Pacific)
Session VI: Novel Therapies on the PTCL Horizon

8:05AM PT | Introductions
Owen A. O'Connor, MD, PhD

8:10AM PT | Adoptive Cellular Treatment of PTCL: Just How Much Longer Should This Take?
Marco Ruella, MD

8:25AM PT | Targeting T-cells with Bispecific Antibodies: Are There any Prospects for Application in PTCL?
Lawrence G. Lum, MD

8:40AM PT | The Newest Small Molecules Under Study in PTCL.
Wei Z. Ai, MD, PhD

8:55AM PT | Monoclonal Antibodies
Wei Z. Ai, MD, PhD

9:10AM PT | The Landscape of New Drugs in Extranodal NK/T-cell Lymphoma
Liang Wang, MD

9:25AM PT | Transformation of Grade I Follicular Lymphoma to Anaplastic Large Cell Lymphoma CD 30 + ALK 1 - with Complete Response to Brentuximab Vedotin and High - Dose Methotrexate
Mubarak Al Mansour, MD

9:40AM PT | Panel Discussion
Owen A. O'Connor, MD, PhD
Marco Ruella, MD
Lawrence G. Lum, MD
Wei Z. Ai, MD, PhD
Liang Wang, MD
Mubarak Al Mansour, MD

Jun 25, 2022
10:10am - 10:20am (Pacific)
Visit Sponsors, Poster Hall & Networking Forum

Visit our Sponsors Wall HERE

Visit our Poster Hall HERE 

Visit our Networking Forum HERE

Jun 25, 2022
10:20am - 11:30am (Pacific)
Session VII: Industry Innovations

10:20AM PT | Introductions
Francine M. Foss, MD

10:25AM PT | Development of allogeneic CAR-T product for T cell malignancies using RNA interference
Hyung Cheol Kim, PhD

10:40AM PT | Engineered Myeloid Cells for T Cell Lymphoma
Michele Gerber, MD

10:55AM PT | How Nanoparticle Chemistry is Changing our Approach to Therapeutics: The mRNA COVID19 Paradigm
Mark Kester, PhD

11:10AM PT | Oral CCR4 Antagonist FLX475 Antitumor Activity Against Extranodal NK/T-cell Lymphoma, Nasal Type
William Ho, MD, PhD

11:25AM PT | Targeting Cell Surface Heat Shock Protein 70 for T-cell Lymphomas
Robert Z. Orlowski, MD, PhD

11:40AM PT | PI3K in PTCL
Bong-Seog Kim, MD, PhD

11:55AM PT | Panel Discussion
Francine M. Foss, MD
Hyung Cheol Kim, PhD
Michelle Gerber, MD
Mark Kester, PhD
William Ho, MD, PhD
Robert Z. Orlowski, MD, PhD
Bong-Seog Kim, MD, PhD

Jun 25, 2022
11:50am - 12:05pm (Pacific)
Session VIII: Wrap-Up Highlights

12:15pm PT | TCLF 2022 Summary Roundtable
Francine M. Foss, MD
Owen A. O'Connor, MD, PhD
John Chan
Miles Prince

12:55pm PT | Closing Remarks
Francine Foss, MD
Owen O'Conner, MD, PhD
Won-Seog Kim, MD, PhD